Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
详细信息    查看全文
  • 作者：Gerasimos Aravantinos (1)
    Dimitrios Pectasides (2)

    1. Second Department of Medical Oncology     ; Agioi Anargiroi Cancer Hospital ; 螝ifisia ; Athens ; Greece
    2. Second Department of Internal Medicine     ; Hippokration Hospital ; University of Athens School of Medicine ; Athens ; Greece
  • 关键词：Angiogenesis ; Bevacizumab ; Fallopian tube cancer ; Ovarian cancer ; Primary peritoneal cancer ; Targeted therapies
  • 刊名：Journal of Ovarian Research
  • 出版年：2014
  • 出版时间：December 2014
  • 年：2014
  • 卷：7
  • 期：1
  • 全文大小：456 KB
  • 参考文献：1. Gaitskell, K, Martinek, I, Bryant, A, Kehoe, S, Nicum, S, Morrison, J (2011) Angiogenesis inhibitors for the treatment of ovarian cancer (review). Cochrane Database Syst Rev.
    2. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D (2011) Global cancer statistics. CA Cancer J Clin 61: pp. 69-90 CrossRef
    3. Shepherd, JH (1989) Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96: pp. 889-892 CrossRef
    4. Colombo, N, Peiretti, M, Parma, G, Lapresa, M, Mancari, R, Carinelli, S, Sessa, C, Castiglione, M (2010) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: pp. v23-v30 CrossRef
    5. Hennessy, BT, Coleman, RL, Markman, M (2009) Ovarian cancer. Lancet 374: pp. 1371-1382 CrossRef
    6. Kim, A, Ueda, Y, Naka, T, Enomoto, T (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 31: pp. 14 CrossRef
    7. Katsumata, N, Yasuda, M, Takahashi, F, Isonishi, S, Jobo, T, Aoki, D, Tsuda, H, Sugiyama, T, Kodama, S, Kimura, E, Ochiai, K, Noda, K (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374: pp. 1331-1338 CrossRef
    8. Katsumata, N, Yasuda, M, Isonishi, S, Takahashi, F, Michimae, H, Kimura, E, Aoki, D, Jobo, T, Kodama, S, Terauchi, F, Sugiyama, T, Ochiai, K (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial. Lancet Oncol 14: pp. 1020-1026 CrossRef
    9. Pignata, S, Scambia, G, Katsaros, D, Gallo, C, Pujade-Lauraine, E, De Placido, S, Bologna, A, Weber, B, Raspagliesi, F, Panici, PB, Cormio, G, Sorio, R, Cavazzini, MG, Ferrandina, G, Breda, E, Murgia, V, Sacco, C, Cinieri, S, Salutari, V, Ricci, C, Pisano, C, Greggi, S, Lauria, R, Lorusso, D, Marchetti, C, Selvaggi, L, Signoriello, S, Piccirillo, MC, Di Maio, M, Perrone, F (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15: pp. 396-405 CrossRef
    10. Chan J, Brady M, Penson R, Monk B, Boente M, Walker J, Davidson S, DiSilvestro P, O鈥橫alley D, Morgan M, Pearl M, De Geest K, Michael H: Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology, Liverpool, UK, October 19鈥?2, 2013
    11. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 1.2013. [http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf]. Accessed 01.02.13
    12. Heintz, AP, Odicino, F, Maisonneuve, P, Quinn, MA, Benedet, JL, Creasman, WT, Ngan, HY, Pecorelli, S, Beller, U (2006) Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95: pp. S161-S192 CrossRef
    13. Monk, BJ, Coleman, RL (2009) Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to non-platinum doublets and adding anti-angiogenesis compounds. Int J Gynecol Cancer 19: pp. S63-S67 CrossRef
    14. Masoumi Moghaddam, S, Amini, A, Morris, DL, Pourgholami, MH (2012) Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 31: pp. 143-162 CrossRef
    15. Geva, E, Jaffe, RB (2000) Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 74: pp. 429-438 CrossRef
    16. Bandiera, E, Franceschini, R, Specchia, C, Bignotti, E, Trevisiol, C, Gion, M, Pecorelli, S, Santin, AD, Ravaggi, A (2012) Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol 2012: pp. 245756
    17. Herr, D, Sallmann, A, Bekes, I, Konrad, R, Holzheu, I, Kreienberg, R, Wulff, C (2012) VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol 127: pp. 210-216 CrossRef
    18. Ramakrishnan, S, Subramanian, IV, Yokoyama, Y, Geller, M (2005) Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8: pp. 169-182 CrossRef
    19. Ferrara, N, Hillan, KJ, Novotny, W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: pp. 328-335 CrossRef
    20. Campos, S, Atkinson, T, Berlin, S, Roche, M, Whalen, C, Matulonis, U, Horowitz, N, Birrer, M, Penson, R (2011) STAC: A phase II study of carboplatin/paclitaxel/bevacizumab followed by randomization to either bevacizumab alone or erlotinib and bevacizumab in the upfront management of patients with ovarian, fallopian tube or peritoneal cancer [abstract]. Gynecol Oncol 120: pp. S79-S181 CrossRef
    21. Burger, RA, Brady, MF, Bookman, MA, Fleming, GF, Monk, BJ, Huang, H, Mannel, RS, Homesley, HD, Fowler, J, Greer, BE, Boente, M, Birrer, MJ, Liang, SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: pp. 2473-2483 CrossRef
    22. Perren, TJ, Swart, AM, Pfisterer, J, Ledermann, JA, Pujade-Lauraine, E, Kristensen, G, Carey, MS, Beale, P, Cervantes, A, Kurzeder, C, du Bois, A, Sehouli, J, Kimmig, R, St盲hle, A, Collinson, F, Essapen, S, Gourley, C, Lortholary, A, Selle, F, Mirza, MR, Leminen, A, Plante, M, Stark, D, Qian, W, Parmar, MK, Oza, AM (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: pp. 2484-2496 CrossRef
    23. Oza, AM, Perren, TJ, Swart, AM, Schr枚der, W, Pujade-Lauraine, E, Havsteen, H, Beale, P, Cervantes, AM, Embleton, AC, Parmar, M (2013) ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer [abstract]. E J Cancer 49: pp. LBA:6
    24. Aghajanian, C, Blank, SV, Goff, BA, Judson, PL, Teneriello, MG, Husain, A, Sovak, MA, Yi, J, Nycum, LR (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30: pp. 2039-2045 CrossRef
    25. Aghajanian C, Nycum LR, Goff B, Nguyen H, Husain A, Blank SV: Updated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine (G) + carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [abstract]. Presented at the ESMO Congress, Vienna, Austria, 28 September 鈥?2 October 2012. Abstract 9670
    26. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote IB, Witteveen P, Bamiaset A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag DT, Ray-Coquard I, and AURELIA Investigators: AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. / J Clin Oncol 2012.,30(Suppl. 18): LBA5002
    27. Witteveen, P, Lortholary, A, Fehm, T, Poveda, A, Reuss, A, Havsteen, H, Raspagliesi, F, Vergote, I, Bamias, A, Pujade-Lauraine, (2013) Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC) [abstract]. E J Cancer 49: pp. LBA:5
    28. Burger, RA, Brady, MF, Rhee, J, Sovak, MA, Nguyen, H, Bookman, MA (2011) Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) [abstract]. J Clin Oncol 29: pp. 5023
    29. Stark, D, Nankivell, M, Pujade-Lauraine, E, Kristensen, G, Elit, L, Stockler, M, Hilpert, F, Cervantes, A, Brown, J, Lanceley, A, Velikova, G, Sabate, E, Pfisterer, J, Carey, MS, Beale, P, Qian, W, Swart, AM, Oza, A, Perren, T (2013) Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 14: pp. 236-243 CrossRef
    30. Stockler, MR, Hilpert, F, Friedlander, M, King, M, Wenzel, LB, Lee, C, Joly, F, Gregorio, ND, Arija, JAA, Mirza, MR, Sorio, R, Freudensprung, U, Sneller, V, Hales, G, Pujade Lauraine, E (2013) Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC) [abstract]. J Clin Oncol 31: pp. 5542
    31. National Cancer Institute: Carboplatin and paclitaxel or oxaliplatin and capecitabine, with or without bevacizumab, as first-line therapy in treating patients with newly diagnosed stage II, stage III, stage IV, or recurrent stage I epithelial ovarian cancer or fallopian tube cancer. National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01081262
    32. National Cancer Institute: Carboplatin and paclitaxel with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. National Library of Medicine. http://www.clinicaltrials.gov/show/NCT00565851
    33. AGO Study Group: Evaluation of optimal initial treatment duration of bevacizumab in combination with standard chemotherapy in patients with ovarian cancer (BOOST). National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01462890
    34. National Cancer Institute: Bevacizumab and intravenous or intraperitoneal chemotherapy in treating patients with stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. National Library of Medicine. http://www.clinicaltrials.gov/show/NCT00951496
    35. National Cancer Institute: Paclitaxel and carboplatin with or without bevacizumab in treating patients with stage II, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01167712
    36. Gonzalez-Martin, A, Gladieff, L, Tholander, B, Stroyakovsky, D, Gore, ME, Segalla, JGM, Reyners, AKL, Kovalenko, N, Oaknin, A, Selle, F, Bollag, DT, Pignata, S (2012) Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA [abstract]. J Clin Oncol 30: pp. 5017
    37. Birrer MJ, Lankes H, Burger RA, Mannel R, Homesley H, Henschel V, Sovak M, Scherer SJ, De Haas S, Pallaud C: Biomarker (BM) results from GOG-0218, a phase 3 trial of front-line bevacizumab (BV) + chemotherapy (CT) for ovarian cancer (OC) [abstract]. Presented at the ESMO Congress, Vienna, Austria, 28 September 鈥?2 October 2012. Abstract 198P
    38. Chambers, SK, Clouser, MC, Baker, AF, Roe, DJ, Cui, H, Brewer, MA, Hatch, KD, Gordon, MS, Janicek, MF, Isaacs, JD, Gordon, AN, Nagle, RB, Wright, HM, Cohen, JL, Alberts, DS (2010) Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 16: pp. 5320-5328 CrossRef
    39. Madsen, CV, Steffensen, KD, Olsen, DA, Waldstr酶m, M, Smerdel, M, Adimi, P, Brandslund, I, Jakobsen, A (2012) Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. J Ovarian Res 5: pp. 23 CrossRef
    40. National Cancer Institute, Naples: Study of clinical and biological prognostic factors in patients with ovarian cancer receiving carboplatin + paclitaxel with bevacizumab (MITO16/MANGO-2). National Library of Medicine identifier: NCT01706120. Available from: http://www.clinicaltrials.gov/show/NCT01706120 [Accessed 01.02.13]
    41. Aghajanian, C, Blank, SV, Goff, BA, Judson, PL, Nycum, LR, Sovak, MA, Yi, J, Husain, A (2012) An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer [abstract]. J Clin Oncol 30: pp. 5054
    42. Matulonis, UA, Berlin, S, Ivy, P, Tyburski, K, Krasner, C, Zarwan, C, Berkenblit, A, Campos, S, Horowitz, N, Cannistra, SA, Lee, H, Lee, J, Roche, M, Hill, M, Whalen, C, Sullivan, L, Tran, C, Humphreys, BD, Penson, RT (2009) Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27: pp. 5601-5606 CrossRef
    43. Ledermann, JA, Perren, TJ, Raja, FA, Embleton, A, Rustin, GJS, Jayson, G, Kaye, SB, Swart, AM, Vaughan, M, Hirte, H (2013) Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial [abstract]. E J Cancer 49: pp. LBA:10
    44. Du Bois, A, Floquet, A, Weon Kim, J, Rau, J, Del Campo, JM, Friedlander, M, Pignata, S, Fujiwara, K, Vergote, I, Colombo, N, Mirza, MR, Monk, BJ, Wimberger, P, Ray-Coquard, I, Zang, R, Diaz-Padilla, I, Baumann, KH, Kim, JH, Harter, P (2013) Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16) [abstract]. J Clin Oncol 31: pp. LBA5503
    45. Campos, SM, Penson, RT, Matulonis, U, Horowitz, NS, Whalen, C, Pereira, L, Tyburski, K, Roche, M, Szymonifka, J, Berlin, S (2013) A phase II trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol 128: pp. 215-220 CrossRef
    46. Biagi, JJ, Oza, AM, Chalchal, HI, Grimshaw, R, Ellard, SL, Lee, U, Hirte, H, Sederias, J, Ivy, SP, Eisenhauer, EA (2011) A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 22: pp. 335-340 CrossRef
    47. Baumann, KH, du Bois, A, Meier, W, Rau, J, Wimberger, P, Sehouli, J, Kurzeder, C, Hilpert, F, Hasenburg, A, Canzler, U, Hanker, LC, Hillemanns, P, Richter, B, Wollschlaeger, K, Dewitz, T, Bauerschlag, D, Wagner, U (2012) A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol 2: pp. 2265-2271 CrossRef
    48. Matei, D, Sill, MW, Lankes, HA, DeGeest, K, Bristow, RE, Mutch, D, Yamada, SD, Cohn, D, Calvert, V, Farley, J, Petricoin, EF, Birrer, MJ (2011) Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 29: pp. 69-75 CrossRef
    49. Herzog, TJ, Scambia, G, Kim, BG, Lhomm茅, C, Markowska, J, Ray-Coquard, I, Sehouli, J, Colombo, N, Shan, M, Petrenciuc, O, Oza, A (2012) A randomized, double-blind, phase 2 trial of maintenance sorafenib in epithelial ovarian or primary peritoneal cancer. Int J Gynecol Cancer 22: pp. E99-E100
    50. Ledermann, JA, Hackshaw, A, Kaye, S, Jayson, G, Gabra, H, McNeish, I, Earl, H, Perren, T, Gore, M, Persic, M, Adams, M, James, L, Temple, G, Merger, M, Rustin, G (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29: pp. 3798-3804 CrossRef
    51. Du Bois, A, Kristensen, G, Ray-Coquard, I, Reuss, A, Pignata, S, Colombo, N, Denison, U, Vergote, I, del Campo, JM, Ottevanger, P, Merger, M, Harter, P (2013) AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer [abstract]. Int J Gyn Cancer 23: pp. LBA1
    52. Coleman, RL, Duska, LR, Ramirez, PT, Modesitt, SC, Schmeler, KM, Iyer, R, Garcia, M, Sood, A (2011) Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer [abstract]. J Clin Oncol 29: pp. 5017
    53. Gotlieb, WH, Amant, F, Advani, S, Goswami, C, Hirte, H, Provencher, D, Somani, N, Yamada, SD, Tamby, J-F, Vergote, I (2012) Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 13: pp. 154-162 CrossRef
    54. Colombo, N, Mangili, G, Mammoliti, S, Kalling, M, Tholander, B, Sternas, L, Buzenet, G, Chamberlain, D (2012) A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 125: pp. 42-47 CrossRef
    55. Karlan, BY, Oza, AM, Richardson, GE, Provencher, DM, Hansen, VL, Buck, M, Chambers, SK, Ghatage, P, Pippitt, CH, Brown, JV, Covens, A, Nagarkar, RV, Davy, M, Leath, CA, Nguyen, H, Stepan, DE, Weinreich, DM, Tassoudji, M, Sun, YN, Vergote, IB (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30: pp. 362-371 CrossRef
    56. Monk, BJ, Poveda, A, Vergote, I, Raspagliesi, F, Fujiwara, K, Bae, DS, Oaknin, A, Navale, L, Warner, DJ, Oza, AM (2013) A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer [abstract]: TRINOVA-1. E J Can cer 49: pp. LBA:41
    57. Amgen: TRINOVA-2: Trebananib in Ovarian Cancer-2. National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01281254
    58. Amgen: TRINOVA-3: A study of AMG 386 or AMG 386 placebo in combination with paclitaxel and carboplatin to treat ovarian cancer. National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01493505
    59. Verheul, HM, Hammers, H, van Erp, K, Wei, Y, Sanni, T, Salumbides, B, Qian, DZ, Yancopoulos, GD, Pili, R (2007) Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13: pp. 4201-4208 CrossRef
    60. Fischer, C, Jonckx, B, Mazzone, M, Zacchigna, S, Loges, S, Pattarini, L, Chorianopoulos, E, Liesenborghs, L, Koch, M, De Mol, M, Autiero, M, Wyns, S, Plaisance, S, Moons, L, van Rooijen, N, Giacca, M, Stassen, JM, Dewerchin, M, Collen, D, Carmeliet, P (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: pp. 463-475 CrossRef
    61. Boehringer Ingelheim: BIBF 1120 in bevacizumab resistant, persistent, or recurrent epithelial ovarian cancer. National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01669798
    62. Matei, D, Chang, DD, Jeng, M-H (2004) Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor 伪 and Aky inactivation. Clin Cancer Res 10: pp. 681-690 CrossRef
    63. Safra, T, Andreopoulou, E, Levinson, B, Borgato, L, Pothuri, B, Blank, S, Tiersten, A, Boyd, L, Curtin, J, Muggia, F (2010) Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer. Anticancer Res 30: pp. 3243-3247
    64. Sonpavde, G, Hutson, TE, Sternberg, CN (2008) Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 17: pp. 253-261 CrossRef
    65. Hahn, O, Stadler, W (2006) Sorafenib. Curr Opin Oncol 18: pp. 615-621 CrossRef
    66. Thompson, DS, Dudley, BS, Bismayer, JA, Gian, VG, Merritt, WM, Whorf, RC, Burris, HA, Hainsworth, JD (2013) Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute [abstract]. J Clin Oncol 31: pp. 5113 CrossRef
    67. Chekerov, R, Mahner, S, Lorenz, R, Hilpert, F, Harter, P, Wagner, U, Klare, P, Sehouli, J (2011) Efficacy and safety of sorafenib added to topotecan in patients with platinum-resistant recurrent ovarian cancer: A NOGGO-AGO intergroup run-in-study (TRIAS). Int J Gynecol Cancer 21: pp. S597 CrossRef
    68. National Cancer Institute: Sorafenib and bevacizumab to treat ovarian, fallopian and peritoneal cancer. National Library of Medicine. http://www.clinicaltrials.gov/show/NCT00436215
    69. Mendel, DB, Laird, AD, Xin, X, Louie, SG, Christensen, JG, Li, G, Schreck, RE, Abrams, TJ, Ngai, TJ, Lee, LB, Murray, LJ, Carver, J, Chan, E, Moss, KG, Haznedar, JO, Sukbuntherng, J, Blake, RA, Sun, L, Tang, C, Miller, T, Shirazian, S, McMahon, G, Cherrington, JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: pp. 327-337
    70. Ye, Q, Chen, H-L (2013) Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. Arch Gynecol Obstet 288: pp. 655-666 CrossRef
  • 刊物主题：Gynecology; Reproductive Medicine;
  • 出版者：BioMed Central
  • ISSN：1757-2215
文摘
As increased angiogenesis has been linked with the progression of ovarian cancer, a number of anti-angiogenic agents have been investigated, or are currently in development, as potential treatment options for patients with advanced disease. Bevacizumab, a recombinant monoclonal antibody against vascular endothelial growth factor, has gained European Medicines Agency approval for the front-line treatment of advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer in combination with carboplatin and paclitaxel, and for the treatment of first recurrence of platinum-sensitive ovarian cancer in combination with carboplatin and gemcitabine. We conducted a systematic literature review to identify available efficacy and safety data for bevacizumab in ovarian cancer as well as for newer anti-angiogenic agents in development. We analyzed published data from randomized, controlled phase II/III clinical trials enrolling women with ovarian cancer to receive treatment with bevacizumab. We also reviewed available data for emerging anti-angiogenic agents currently in phase II/III development, including trebananib, aflibercept, nintedanib, cediranib, imatinib, pazopanib, sorafenib and sunitinib. Significant efficacy gains were achieved with the addition of bevacizumab to standard chemotherapy in four randomized, double-blind, phase III trials, both as front-line treatment (GOG-0218 and ICON7) and in patients with recurrent disease (OCEANS and AURELIA). The type and frequency of bevacizumab-related adverse events was as expected in these studies based on published data. Promising efficacy data have been published for a number of emerging anti-angiogenic agents in phase III development for advanced ovarian cancer. Further research is needed to identify predictive or prognostic markers of response to bevacizumab in order to optimize patient selection and treatment benefit. Data from phase III trials of newer anti-angiogenic agents in ovarian cancer are awaited.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700